Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman, Axel Hauschild, Caroline Robert, John B.A.G. Haanen, Paolo A. Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio, David Hogg, Paul Lorigan, Célèste Lebbé, Thomas Jouary, Dirk Schadendorf, Antoni Ribas, Steven O’Day, Jeffrey A. Sosman, John M. Kirkwood, Alexander M.M. Eggermont, Brigitte Dréno, K. B. Nolop, Jiang Li, B. Nelson, Jeannie Hou, Richard J. Lee, Keith T. Flaherty, Grant A. McArthur

New England Journal of Medicine, 2011

Memorial Sloan Kettering Cancer Center, Kiel University, Institut Gustave Roussy, The Netherlands Cancer Institute, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Royal Marsden Hospital, University of Zurich, University of Tübingen, European Institute of Oncology, Tumour Institute of Tuscany, University Health Network, Princess Margaret Cancer Centre, University of Manchester, Hôpital Saint-Louis, Hôpital Saint-André, Essen University Hospital, University of California, Los Angeles, Angeles Clinic and Research Institute, Vanderbilt University, University of Pittsburgh, Nantes Université, La Roche College, Massachusetts General Hospital, Peter MacCallum Cancer Centre

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

7657

Citations

View on Google Scholar

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Abstract

Journal Details

Join JournalsHub

Welcome Back